Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

NCT02917772 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Renal Cell
Clear-cell Metastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL: Nivolumab/Ipilimumab

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]